Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N, Castillo C, Mosteiro M, Pérez X, Aguilar S, Ruíz-Pace F, Gil M, Cuadra C, Ruffinelli JC, Martínez M, Losa F, Soler G, Teulé À, Castany R, Gallego R, Ruíz A, Garralda E, Élez E, Vivancos A, Tabernero J, Salazar R, Dienstmann R, Santos Vivas C. Mulet Margalef N, et al. Among authors: losa f. Mol Oncol. 2023 Sep;17(9):1908-1916. doi: 10.1002/1878-0261.13444. Epub 2023 Jun 12. Mol Oncol. 2023. PMID: 37097008 Free PMC article.
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Garcia-Alfonso P, et al. Among authors: losa f. BMC Cancer. 2015 Apr 29;15:327. doi: 10.1186/s12885-015-1293-y. BMC Cancer. 2015. PMID: 25925749 Free PMC article. Clinical Trial.
Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.
Salazar R, Navarro M, Losa F, Alonso V, Gallén M, Rivera F, Benavides M, Escudero P, González E, Massutí B, Gómez A, Majem M, Aranda E. Salazar R, et al. Among authors: losa f. Clin Transl Oncol. 2012 Aug;14(8):592-8. doi: 10.1007/s12094-012-0846-7. Epub 2012 Jul 11. Clin Transl Oncol. 2012. PMID: 22855141 Clinical Trial.
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.
García M, Martinez-Villacampa M, Santos C, Navarro V, Teule A, Losa F, Pisa A, Cambray M, Soler G, Lema L, Kreisler E, Figueras A, Juan XS, Viñals F, Biondo S, Salazar R. García M, et al. Among authors: losa f. BMC Cancer. 2015 Feb 26;15:59. doi: 10.1186/s12885-015-1052-0. BMC Cancer. 2015. PMID: 25886275 Free PMC article. Clinical Trial.
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Santos C, et al. Among authors: losa f. Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16. Mol Cancer Ther. 2017. PMID: 28626084 Free article.
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C. Vidal J, et al. Among authors: losa f. Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005. Ann Oncol. 2019. PMID: 30689692 Free article.
Short-course radiotherapy in stage IV rectal cancer with resectable disease.
Cambray M, González-Viguera J, Macià M, Losa F, Soler G, Frago R, Mullerat JM, Castellví J, Guinó E. Cambray M, et al. Among authors: losa f. Clin Transl Oncol. 2021 Dec;23(12):2482-2488. doi: 10.1007/s12094-021-02647-0. Epub 2021 Jun 3. Clin Transl Oncol. 2021. PMID: 34081292
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Élez E, Gómez-España MA, Grávalos C, García-Alfonso P, Ortiz-Morales MJ, Losa F, Díaz IA, Graña B, Toledano-Fonseca M, Valladares-Ayerbes M, Polo E, Salgado M, Martínez de Castro E, Safont MJ, Salud A, Ruiz-Casado A, Tabernero J, Riesco MDC, Rodriguez-Ariza A, Aranda E. Élez E, et al. Among authors: losa f. Br J Cancer. 2022 Apr;126(6):874-880. doi: 10.1038/s41416-021-01638-w. Epub 2021 Dec 22. Br J Cancer. 2022. PMID: 34937947 Free PMC article. Clinical Trial.
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Vidal J, Fernández-Rodríguez MC, Casadevall D, García-Alfonso P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, Garcia-Carbonero R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Vidal J, et al. Among authors: losa f. Clin Cancer Res. 2023 Jan 17;29(2):379-388. doi: 10.1158/1078-0432.CCR-22-1696. Clin Cancer Res. 2023. PMID: 36074154
83 results